Aptose Biosciences Inc

Aptose Biosciences Inc. is a clinical-stage biotechnology company based in San Diego, California. The company employs 39 people and reported $0.283 million in revenue. Aptose Biosciences is developing targeted therapies for hematologic malignancies. Their lead product candidate, CG-806, is an oral FLT3/BTK inhibitor being investigated for the treatment of B-cell malignancies like chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin’s lymphomas. CG-806 is also being explored as a treatment for relapsed or refractory acute myeloid leukemia, including patients who are resistant to existing targeted therapies. Additionally, Aptose Biosciences is developing APTO-253, a first-in-class MYC inhibitor, for patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome. Aptose Biosciences focuses on developing first-in-class targeted agents to address unmet medical needs in hematologic cancers. For more information about Aptose Biosciences Inc., please visit their website at aptose.com.